<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00884884</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAA-Swift-AA015753</org_study_id>
    <secondary_id>NIH Grant 5RO1AA015753-02</secondary_id>
    <nct_id>NCT00884884</nct_id>
  </id_info>
  <brief_title>Aripiprazole and Topiramate on Free-Choice Alcohol Use</brief_title>
  <acronym>AT</acronym>
  <official_title>Aripiprazole and Topiramate on Free-Choice Alcohol Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study investigates the effects of two potential alcohol treatment medications on&#xD;
      drinking in a laboratory setting. Aripiprazole (APZ), effects dopamine and serotonin&#xD;
      receptors with fewer limiting side effects seen with other atypical antipsychotics.&#xD;
      Topiramate (TPMT), an antiepileptic, affects glutamate and GABA-A receptors and shows promise&#xD;
      in reducing heavy drinking. Few studies have used two medications with such a diverse&#xD;
      combination of actions to examine a potential synergistic effect on reducing alcohol&#xD;
      consumption.&#xD;
&#xD;
      The primary aims are to:&#xD;
&#xD;
        1. determine if APZ and TPMT are each more effective than placebo, and the combination of&#xD;
           APZ and TPMT is more effective than either drug alone or placebo, in reducing alcohol&#xD;
           use in non-treatment seeking alcohol dependent subjects in a laboratory based alcohol&#xD;
           self-administration experiment (ASAE)&#xD;
&#xD;
        2. examine a hypothesized dose-response for three doses of APZ (0, 7.5 mg/d and 15 mg/d)&#xD;
           along with three doses of TPMT (0, 100mg/d and 200mg/d)&#xD;
&#xD;
        3. examine the putative mechanisms of action of APZ, TPMT alone and together on craving,&#xD;
           subjective stimulation, candidate gene influences and other behavioral effects&#xD;
           associated with alcohol consumption&#xD;
&#xD;
        4. establish the safety of giving APZ and TPMT together. Non-treatment seeking, alcohol&#xD;
           dependent Participants (N=216) will be recruited from the community and randomly&#xD;
           assigned to one of the 9 cells. Subjects drinking and safety is monitored over a 5-week&#xD;
           titration to their target dose, leading to an in-laboratory alcohol self administration&#xD;
           session, during which clinical and behavioral effects are assessed during access to&#xD;
           alcohol. A 1 month follow-up assesses adverse events and drinking.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to the modest effect of current pharmacotherapies, more effective treatments must be&#xD;
      developed to optimally treat alcohol dependent patients. Treatments combining&#xD;
      pharmacotherapies with different mechanisms of action may better address the diverse&#xD;
      neurobiology of alcohol and the heterogeneity of alcoholics. However, little is known about&#xD;
      how medication may affect behavior to reduce drinking. Aripiprazole (APZ), a partial dopamine&#xD;
      agonist, affects dopamine and serotonin receptors without the limiting side effects seen with&#xD;
      other atypical antipsychotics. Dopamine mediates reward based drinking and craving.&#xD;
      Topiramate (TPMT), an antiepileptic, affects glutamate and GABA-A receptors and shows promise&#xD;
      in reducing heavy drinking. Glutamate and GABA may mediate relief-based drinking and&#xD;
      protracted withdrawal. Despite strong evidence that multiple neurotransmitters contribute to&#xD;
      alcoholism, few studies have used two medications with such a diverse combination of actions&#xD;
      to examine a potential synergistic effect on reducing alcohol consumption.&#xD;
&#xD;
      The present study will recruit 216 healthy, alcohol-dependent volunteers who are not&#xD;
      currently seeking treatment for their alcohol dependence to learn more about how these&#xD;
      medications may work.&#xD;
&#xD;
      The primary aims are to: (1) determine if APZ and TPMT are each more effective than placebo,&#xD;
      and the combination of APZ and TPMT is more effective than either drug alone or placebo, in&#xD;
      reducing alcohol use in non-treatment seeking alcohol dependent subjects in an alcohol self&#xD;
      administration experiment (ASAE); (2) examine a hypothesized dose-response for three doses of&#xD;
      APZ (0, 7.5mg/d and 15 mg/d) and three doses of TPMT (0, 100mg/d, 200mg/d); (3) examine the&#xD;
      putative mechanisms of action of APZ, TPMT alone and together on craving, subjective&#xD;
      stimulation, candidate gene influences and other behavioral effects associated with alcohol&#xD;
      consumption; and (4) establish the safety of giving APZ and TPMT together. We will use of a 3&#xD;
      X 3 drug (7.5mg, 15mg APZ vs. placebo) by drug (100mg, 200mg TPMT vs. placebo)&#xD;
      between-subjects factorial design. Participants are randomly assigned to one of 9 cells.&#xD;
      Subjects drinking and safety is monitored over a 5-week titration to their target dose,&#xD;
      leading to an in-laboratory alcohol self administration session, during which clinical and&#xD;
      behavioral effects are assessed during access to alcohol. A 1 month follow-up assesses&#xD;
      adverse events and drinking. The long term objectives of this research are to improve&#xD;
      medications available for alcoholism treatment and inform research and theory on the&#xD;
      mechanisms of action of such medications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of alcoholic drinks consumed in a laboratory setting</measure>
    <time_frame>90 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of the medications singly and in combination, compared to placebo</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drinks consumed during the medication titration period</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>Double Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aripiprazole 15, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg Aripiprazole, Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aripiprazole 7.5, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aripiprazole 7.5 mg daily plus Placebo daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topiramate 100mg, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topiramate 100 mg daily plus Placebo daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topiramate 200, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topiramate 200 mg daily plus Placebo daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topiramate 100, Aripiprazole 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topiramate 100 daily plus, Aripiprazole 5mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topiramate 200, Aripiprazole 15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topiramate 200 mg daily plus Aripiprazole 15mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topiramate 100, Aripiprazole 7.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topiramate 100 mg daily, Aripiprazole 7.5 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topiramate 200, Aripiprazole 7.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topiramate 200 mg daily plus Aripiprazole 7.5mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Double Placebo</intervention_name>
    <description>1 capsule daily</description>
    <arm_group_label>Double Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole 15, placebo</intervention_name>
    <description>15 mg Aripiprazole daily plus placebo daily</description>
    <arm_group_label>Aripiprazole 15, Placebo</arm_group_label>
    <other_name>Abilify, Topamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole 7.5, Placebo</intervention_name>
    <description>Aripiprazole 7.5 mg daily plus Placebo daily</description>
    <arm_group_label>Aripiprazole 7.5, Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate 100, Placebo</intervention_name>
    <description>Topiramate 100 mg daily plus Placebo daily</description>
    <arm_group_label>Topiramate 100mg, Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate 200, Placebo</intervention_name>
    <description>Topiramate 200 mg daily plus Placebo daily</description>
    <arm_group_label>Topiramate 200, Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate 100, Aripiprazole 15</intervention_name>
    <description>Topiramate 100 mg daily plus Aripiprazole 15mg daily</description>
    <arm_group_label>Topiramate 100, Aripiprazole 5</arm_group_label>
    <other_name>Abilify, Topamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate 100, Aripiprazole 7.5</intervention_name>
    <description>Topiramate 100 mg daily plus Aripiprazole 7.5mg daily</description>
    <arm_group_label>Topiramate 100, Aripiprazole 7.5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate 100, Aripiprazole 15mg</intervention_name>
    <description>Topiramate 100 mg daily plus Aripiprazole 15mg daily</description>
    <arm_group_label>Topiramate 100, Aripiprazole 5</arm_group_label>
    <other_name>Abilify</other_name>
    <other_name>Topamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate 200, Aripiprazole 7.5mg</intervention_name>
    <description>Topiramate 200 mg daily plus Aripiprazole 7.5mg daily</description>
    <arm_group_label>Topiramate 200, Aripiprazole 7.5mg</arm_group_label>
    <other_name>Abilify</other_name>
    <other_name>Topamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate 200, Aripiprazole 15</intervention_name>
    <description>Topiramate 200mg daily plus Aripiprazole 15mg daily</description>
    <arm_group_label>Topiramate 200, Aripiprazole 15</arm_group_label>
    <other_name>Abilify</other_name>
    <other_name>Topamax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  must be non-treatment seeking for alcohol dependence&#xD;
&#xD;
          -  a current DSM-IV-TR diagnosis of alcohol dependence supported by the Structured&#xD;
             Clinical Interview for DSM-IV-TR Axis I Disorders Patient Edition (SCID-I/P a minimum&#xD;
             of ≥ 35drinks a week for men or ≥ 28 or more drinks a week for women&#xD;
&#xD;
          -  must be suitable for outpatient treatment&#xD;
&#xD;
          -  able to read English at an eighth grade level, understand their rights as provided by&#xD;
             the informed consent, and be willing to sign an informed consent to participate in the&#xD;
             study&#xD;
&#xD;
          -  be between 21 and 65 years on age (inclusive)&#xD;
&#xD;
          -  provide evidence of stable residence in the two months prior to enrollment and no&#xD;
             plans to move for the next four months&#xD;
&#xD;
          -  provide a verifiable contact person prior to randomization&#xD;
&#xD;
          -  be in generally good health as determined by the physical exam, medical history, ECG&#xD;
             and laboratory tests&#xD;
&#xD;
          -  have a Body Mass Index &gt;18kg/m2 and &lt; 33 kg/m2&#xD;
&#xD;
          -  if female, must be postmenopausal practicing an effective method of birth control,&#xD;
             have negative pregnancy tests at randomization and before the ASAE;&#xD;
&#xD;
          -  be willing to be adherent to medication dosing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  clinically significant medical abnormalities (i.e. ECG, hematological assessment,&#xD;
             bilirubin &gt; 150% of the upper limit of normal or ALT or AST elevations &gt;300% the upper&#xD;
             limit of normal, biochemistry including urinalysis, electrolytes,). (Persons with&#xD;
             medical conditions that are adequately controlled by their primary care physician will&#xD;
             not be excluded.)&#xD;
&#xD;
          -  have significant alcohol withdrawal symptoms (clinical institute withdrawal assessment&#xD;
             for alcohol revised (CIWA-Ar) &gt;10&#xD;
&#xD;
          -  a history of suicide; history of renal impairment or nephrolithiasis; creatinine&#xD;
             clearance of &lt;60 dl/minute&#xD;
&#xD;
          -  pregnant or lactating or not using an adequate form of birth control&#xD;
&#xD;
          -  taking other medications that may have an effect on alcohol consumption or are&#xD;
             carbonic anhydrase inhibitors&#xD;
&#xD;
          -  clinically significant diseases of the gastrointestinal system or active liver&#xD;
             disease; subjects compelled to receive treatment to avoid imprisonment or loss of&#xD;
             employment&#xD;
&#xD;
          -  previously with a history of adverse reaction or hypersensitivity to either Topiramate&#xD;
             or aripiprazole&#xD;
&#xD;
          -  have a diagnosis of with schizophrenia or bipolar disorder and/or taking&#xD;
             antipsychotics and other drugs that inhibit CYP3A4 or CYP2D6 isoenzymes&#xD;
&#xD;
          -  history of seizures (e.g. epilepsy)&#xD;
&#xD;
          -  patients currently diagnosed with a substance dependence diagnosis other than alcohol&#xD;
             or tobacco&#xD;
&#xD;
          -  patients who have participated in any clinical trial with an investigational agent&#xD;
             within the past 30 days&#xD;
&#xD;
          -  individuals with a reasonable expectation of being institutionalized during the course&#xD;
             of the trial or pending legal charges&#xD;
&#xD;
          -  pregnant or nursing women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert M Swift, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brown University Center for Addiction Studies</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>April 20, 2009</study_first_submitted>
  <study_first_submitted_qc>April 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2009</study_first_posted>
  <last_update_submitted>October 5, 2015</last_update_submitted>
  <last_update_submitted_qc>October 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</investigator_affiliation>
    <investigator_full_name>Robert Swift</investigator_full_name>
    <investigator_title>Professor of Psychiatry and Human Behavior</investigator_title>
  </responsible_party>
  <keyword>Alcohol dependence</keyword>
  <keyword>alcohol abuse</keyword>
  <keyword>topiramate</keyword>
  <keyword>aripiprazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

